To investigate whether IFN-α could cooperate with azacitidine and romidepsin in hampering the metastatic potential of KRAS-mutated CRC cells, we first identified the effective combination dose with the minimum potential toxicity. The gene discussed is IFNA2; the disease is colorectal carcinoma.